Unlicensed Drugs
Mostrando 1-5 de 5 artigos, teses e dissertações.
-
1. Use of unlicensed and off-label drugs in neonates in a Brazilian university hospital
ABSTRACT This study was designed to investigate the use of off-label and unlicensed drugs in a Neonatal Care Unit (NCU) and to compare the frequency of use of off-label drugs according to the drug regulatory agencies in Brazil (Agência Nacional de Vigilância Sanitária-ANVISA) and the United States Food and Drug Administration (FDA). A prospective observat
Braz. J. Pharm. Sci.. Publicado em: 01/02/2018
-
2. The use of unlicensed and off label medicines for children admitted to the neonatal intensive care unit of a median complexity university Hospital in São Paulo / Perfil da utilização de medicamentos não licenciados e sem indicação para crianças em UTI neonatal de Hospital Universitário de média complexidade
Introduction. In pediatrics utilization of unlicensed an off-label drugs are a common practice and this account for ethical and economic reasons. The utilization of unlicensed and off label drugs is not illegal, but can expose patients to risk of harm. Physicians and pharmacists have legal responsibility for any adverse event that may result from this use. S
Publicado em: 2009
-
3. Medicamentos potencialmente perigosos, não aprovados e de uso off label em prescrições pediátricas de um hospital universitário / High-alert medications, unlicensed and off label use in pediatric prescriptions of a university hospital in southern Brazil
Objetivos: Descrever o uso e determinar a prevalência de medicamentos potencialmente perigosos e de uso off label e não aprovados em prescrições de unidades de pediatria geral de um hospital universitário no sul do Brasil. Método: Estudo transversal, realizado de novembro de 2007 a janeiro de 2008, envolvendo pacientes até 14 anos de idade, com perío
Publicado em: 2009
-
4. Unlicensed and off label prescription of drugs to children: population based cohort study
BMJ.
-
5. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Two new drugs provide startling benefits in the treatment of age‐related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years.
BMJ Group.